Compare Amgen, Inc. (AMGN) vs Box Inc (BOX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Box Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Box Inc trades at $28.64 (market cap $3.97B). The key difference: Amgen, Inc. is far larger — about 49.4× Box Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Box Inc pays none. Which is the better fit depends on your goals.
| AMGN | BOX | |
|---|---|---|
Market Cap | $196.12B | $3.97B |
Sector | Health | Technology |
52-Week High | $388.16 | $33.55 |
52-Week Low | $271.18 | $21.37 |
Enterprise Value | $241.41B | $4.52B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
BOX trades at $28.64, down 0.56% today, with strong analyst support (17 Buy, 10 Hold, 1 Sell) and a $37.00 consensus price target representing 29% upside. The company shows robust revenue growth from $874M in 2022 to $1.09B in 2025, with net income surging to $244.62M. Recent expansion of Box Zones in Switzerland, Israel, and Singapore (Business Wire, June 30, 2026) enhances global data governance capabilities. Technical indicators show bullish moving averages but overbought RSI levels.
BOX presents a compelling growth story with expanding profitability and strategic international expansion, though elevated valuation multiples (P/E 44.75) require continued execution. Key risks include competitive cloud storage pressures and debt levels, while institutional sentiment remains positive with significant upside to price targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Box Inc
Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature that enhance workflow management and collaboration.
Read more on BOX →
